BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

252 related articles for article (PubMed ID: 21909374)

  • 1. Stressing the ubiquitin-proteasome system without 20S proteolytic inhibition selectively kills cervical cancer cells.
    Anchoori RK; Khan SR; Sueblinvong T; Felthauser A; Iizuka Y; Gavioli R; Destro F; Isaksson Vogel R; Peng S; Roden RB; Bazzaro M
    PLoS One; 2011; 6(8):e23888. PubMed ID: 21909374
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Chalcone-based small-molecule inhibitors attenuate malignant phenotype via targeting deubiquitinating enzymes.
    Issaenko OA; Amerik AY
    Cell Cycle; 2012 May; 11(9):1804-17. PubMed ID: 22510564
    [TBL] [Abstract][Full Text] [Related]  

  • 3. SAHA shows preferential cytotoxicity in mutant p53 cancer cells by destabilizing mutant p53 through inhibition of the HDAC6-Hsp90 chaperone axis.
    Li D; Marchenko ND; Moll UM
    Cell Death Differ; 2011 Dec; 18(12):1904-13. PubMed ID: 21637290
    [TBL] [Abstract][Full Text] [Related]  

  • 4. NRF3-POMP-20S Proteasome Assembly Axis Promotes Cancer Development via Ubiquitin-Independent Proteolysis of p53 and Retinoblastoma Protein.
    Waku T; Nakamura N; Koji M; Watanabe H; Katoh H; Tatsumi C; Tamura N; Hatanaka A; Hirose S; Katayama H; Tani M; Kubo Y; Hamazaki J; Hamakubo T; Watanabe A; Murata S; Kobayashi A
    Mol Cell Biol; 2020 Apr; 40(10):. PubMed ID: 32123008
    [TBL] [Abstract][Full Text] [Related]  

  • 5. α,β-Unsaturated carbonyl system of chalcone-based derivatives is responsible for broad inhibition of proteasomal activity and preferential killing of human papilloma virus (HPV) positive cervical cancer cells.
    Bazzaro M; Anchoori RK; Mudiam MK; Issaenko O; Kumar S; Karanam B; Lin Z; Isaksson Vogel R; Gavioli R; Destro F; Ferretti V; Roden RB; Khan SR
    J Med Chem; 2011 Jan; 54(2):449-56. PubMed ID: 21186794
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Simultaneous inhibition of hsp 90 and the proteasome promotes protein ubiquitination, causes endoplasmic reticulum-derived cytosolic vacuolization, and enhances antitumor activity.
    Mimnaugh EG; Xu W; Vos M; Yuan X; Isaacs JS; Bisht KS; Gius D; Neckers L
    Mol Cancer Ther; 2004 May; 3(5):551-66. PubMed ID: 15141013
    [TBL] [Abstract][Full Text] [Related]  

  • 7. MDA-7/IL-24, a novel tumor suppressor/cytokine is ubiquitinated and regulated by the ubiquitin-proteasome system, and inhibition of MDA-7/IL-24 degradation enhances the antitumor activity.
    Gopalan B; Shanker M; Scott A; Branch CD; Chada S; Ramesh R
    Cancer Gene Ther; 2008 Jan; 15(1):1-8. PubMed ID: 17828282
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of inhibition of the ubiquitin-proteasome system and Hsp90 on growth and survival of rhabdomyosarcoma cells in vitro.
    Peron M; Bonvini P; Rosolen A
    BMC Cancer; 2012 Jun; 12():233. PubMed ID: 22691173
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Chaperone-mediated 26S proteasome remodeling facilitates free K63 ubiquitin chain production and aggresome clearance.
    Nanduri P; Hao R; Fitzpatrick T; Yao TP
    J Biol Chem; 2015 Apr; 290(15):9455-64. PubMed ID: 25713068
    [TBL] [Abstract][Full Text] [Related]  

  • 10. PDZ Domain-Containing Protein NHERF-2 Is a Novel Target of Human Papillomavirus 16 (HPV-16) and HPV-18.
    Saidu NEB; Filić V; Thomas M; Sarabia-Vega V; Đukić A; Miljković F; Banks L; Tomaić V
    J Virol; 2019 Dec; 94(1):. PubMed ID: 31597772
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Both Rb and E7 are regulated by the ubiquitin proteasome pathway in HPV-containing cervical tumor cells.
    Wang J; Sampath A; Raychaudhuri P; Bagchi S
    Oncogene; 2001 Aug; 20(34):4740-9. PubMed ID: 11498796
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Apigenin manipulates the ubiquitin-proteasome system to rescue estrogen receptor-β from degradation and induce apoptosis in prostate cancer cells.
    Singh V; Sharma V; Verma V; Pandey D; Yadav SK; Maikhuri JP; Gupta G
    Eur J Nutr; 2015 Dec; 54(8):1255-67. PubMed ID: 25408199
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combined inhibition of Hsp90 and the proteasome affects NSCLC proteostasis and attenuates cell migration.
    Zismanov V; Drucker L; Gottfried M
    Anticancer Drugs; 2014 Oct; 25(9):998-1006. PubMed ID: 25153785
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Y-632 inhibits heat shock protein 90 (Hsp90) function by disrupting the interaction between Hsp90 and Hsp70/Hsp90 organizing protein, and exerts antitumor activity in vitro and in vivo.
    Wang W; Liu Y; Zhao Z; Xie C; Xu Y; Hu Y; Quan H; Lou L
    Cancer Sci; 2016 Jun; 107(6):782-90. PubMed ID: 27002306
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inhibition of proteasome deubiquitinating activity as a new cancer therapy.
    D'Arcy P; Brnjic S; Olofsson MH; Fryknäs M; Lindsten K; De Cesare M; Perego P; Sadeghi B; Hassan M; Larsson R; Linder S
    Nat Med; 2011 Nov; 17(12):1636-40. PubMed ID: 22057347
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Degradation of p53 by natural variants of the E6 protein of human papillomavirus type 16.
    Yi JW; Jang M; Kim SJ; Kim SS; Rhee JE
    Oncol Rep; 2013 Apr; 29(4):1617-22. PubMed ID: 23404471
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Proteasome inhibitor MG132 sensitizes HPV-positive human cervical cancer cells to rhTRAIL-induced apoptosis.
    Hougardy BM; Maduro JH; van der Zee AG; de Groot DJ; van den Heuvel FA; de Vries EG; de Jong S
    Int J Cancer; 2006 Apr; 118(8):1892-900. PubMed ID: 16287099
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Proteotoxic stress targeted therapy (PSTT): induction of protein misfolding enhances the antitumor effect of the proteasome inhibitor bortezomib.
    Neznanov N; Komarov AP; Neznanova L; Stanhope-Baker P; Gudkov AV
    Oncotarget; 2011 Mar; 2(3):209-21. PubMed ID: 21444945
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of shRNA-mediated silencing of PSMA7 on cell proliferation and vascular endothelial growth factor expression via the ubiquitin-proteasome pathway in cervical cancer.
    Ren CC; Yang L; Liu L; Chen YN; Cheng GM; Zhang XA; Liu H
    J Cell Physiol; 2019 May; 234(5):5851-5862. PubMed ID: 29247526
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A boronic-chalcone derivative exhibits potent anticancer activity through inhibition of the proteasome.
    Achanta G; Modzelewska A; Feng L; Khan SR; Huang P
    Mol Pharmacol; 2006 Jul; 70(1):426-33. PubMed ID: 16636137
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.